What Алмонт Treats: Main Uses and Benefits

Алмонт (Montelukast) is primarily used for managing and assisting with conditions characterized by periods of heightened symptoms in the respiratory and allergic domains. The medicine is a leukotriene receptor antagonist, which is applied in addressing symptoms related to inflammatory or irritative states in the respiratory system.

The medication is commonly used across the following therapeutic areas: prophylaxis and chronic treatment of asthma, assisting with exercise-induced bronchoconstriction (EIB), and supporting the management of symptoms of allergic rhinitis (seasonal and perennial).

The use of this medication is applied in clinical settings that involve acute or unstable symptom patterns and contributes to improved comfort by addressing inflammatory and irritative states in the airways. It is commonly used to help with managing symptoms that appear suddenly or fluctuate. This approach may assist with maintaining functional stability, especially during episodes of heightened discomfort.

“The medication supports patients during episodes of heightened discomfort by easing the overall symptom burden.”

Quick Fact: Support for Symptoms related to inflammatory or irritative states

---

The official regulatory documentation strictly defines the eligible and ineligible populations for Алмонт (Montelukast).

---

Eligibility Restrictions

Classification	Affected Population	Restriction Basis
Contraindicated	Patients with known hypersensitivity to the active substance or any product component.	Formal exclusion based on allergy risk.
Restricted Use	Patients with allergic rhinitis whose symptoms are mild or who can be adequately treated with alternative therapies.	The FDA advises reserving use only for patients with an inadequate response or intolerance to alternative treatments.
Special Consideration	Patients with Phenylketonuria (PKU).	Chewable tablet formulations contain phenylalanine and require careful dietary evaluation.

---

Age-Related Eligibility

The minimum age for use is dependent on the condition being treated, as established by safety and efficacy studies:

• Asthma: Eligible for patients 12 months of age and older.
• Perennial Allergic Rhinitis: Eligible for patients 6 months of age and older.
• Seasonal Allergic Rhinitis: Eligible for patients 2 years of age and older.
• Exercise-Induced Bronchoconstriction: Eligible for patients 6 years of age and older.

The medicine is not indicated for use in the reversal of acute asthma attacks, and its safety and effectiveness have not been established in pediatric patients younger than the minimum specified age for each respective condition.

The official interaction profile for the active ingredients in Алмонт (Montelukast, Doxofylline, and Levocetirizine) is structured around pharmacokinetic modification and specific pharmacodynamic constraints defined in regulatory documents.

Interacting Substance/Class	Official Regulatory Outcome/Restriction	Classification
Rifampicin	Decreases Montelukast plasma exposure (AUC) by approximately 40% via enzyme induction.	Clinically Significant PK
Aspirin / NSAIDs	Mandatory avoidance in patients with known aspirin sensitivity due to documented risk of adverse reactions.	Contraindicated Combination
Alcohol / CNS Depressants	Co-administration with Levocetirizine should be avoided due to additive central nervous system impairment.	Pharmacodynamic Constraint
Other Xanthine Derivatives	The Doxofylline component must not be administered with other xanthine derivatives.	Prohibited Combination

Montelukast's pharmacokinetics are officially stable when co-administered with drugs such as Theophylline, Warfarin, Prednisone, and oral contraceptives, with regulatory studies finding no clinically important effects that necessitate dosage adjustment. Timing-based restrictions apply, noting Montelukast must not be abruptly substituted for inhaled or oral corticosteroids. Furthermore, while patients with mild-to-moderate hepatic impairment exhibit decreased Montelukast metabolism, regulatory guidance specifies no dosage adjustment is required in this population. The profile confirms that most interactions are classified as clinically monitored or contraindicated for specific patient groups.

The core mechanism involves the selective antagonism of two primary receptor systems: the Cysteinyl Leukotriene Receptor 1 (CysLT1) by montelukast and the Histamine H1 receptor by levocetirizine. This dual receptor blockade prevents the binding of pro-inflammatory lipid and amine mediators, suppressing signal transduction cascades that lead to bronchial smooth muscle contraction, mucosal edema, and changes in neurogenic signaling and vascular permeability.

The addition of doxofylline introduces a complementary mechanism focused on Intracellular Signaling Modulation. Doxofylline acts as a non-selective inhibitor of Phosphodiesterase (PDE) enzymes (specifically PDE III and IV), which prevents the breakdown of cyclic AMP (cAMP). This action elevates intracellular cAMP levels, initiating a cascade that results in direct relaxation of constricted airway muscles and contributing to enhanced modulation of bronchial smooth muscle tone.

The components engage mechanisms that operate on independent biochemical pathways, resulting in mechanistic synergy that impacts multiple physiological systems. The mechanism functions as a sustained blockade of receptor activity; its onset kinetics are biologically constrained, limiting the ability to immediately reverse high-level smooth muscle contraction.

How to Use Алмонт (Montelukast)

Алмонт, containing the active ingredient Montelukast, is administered via the oral route as tablets or oral granules. Its usage is standardized and based on guidelines focusing on consistent daily intake and specific timing. The medicine is intended for long-term, chronic management and should be continued even during periods of symptom control.

---

Official Administration Schedule

Usage Context	Standard Adult Dose (Age ge 15)	Dosing Frequency	Timing Constraint
Asthma/Chronic Management	10 mg film-coated tablet	Once daily	Recommended in the evening
Allergic Rhinitis (Alone)	10 mg film-coated tablet	Once daily	Morning or evening
EIB Prophylaxis	10 mg film-coated tablet	Single dose	At least 2 hours before exercise

---

Use Patterns and Preparation

The most commonly used strength for adults is the 10 mg film-coated tablet. This dose may be taken with or without food. If a dose is already taken daily for asthma or rhinitis, an additional dose should not be taken for exercise-induced bronchoconstriction.

For pediatric patients, specific strengths are used, including 4 mg oral granules for the youngest age group. These granules must be mixed with specified cold or room-temperature soft foods or liquids and must be administered entirely within 15 minutes of opening the packet to ensure the full dose is received. No dose adjustment is required for elderly patients or those with mild to moderate kidney or liver impairment.

Research evidence / Overview of studies for Алмонт (Montelukast)

Evidence for Chronic Treatment of Asthma

Research exploring the use of Montelukast for the long-term management of asthma symptoms has relied on Randomized Controlled Trials (RCTs) and systematic reviews, primarily focusing on patients with mild-to-moderate persistent asthma. Researchers have examined specific outcomes related to physical discomfort and functional imbalance, such as changes in objective pulmonary function markers (e.g., FEV1) and the frequency of asthma exacerbations. Findings described in these studies reflect how symptoms evolved in the observed populations over defined time intervals, often ranging from 4 to 48 weeks. Certain systematic reviews noted that the reported magnitude of effect on exacerbation rates differed when compared directly against standard inhaled corticosteroid monotherapy.

Evidence for Allergic Rhinitis and Combination Use

Montelukast was studied for its use in exploring patterns of symptoms associated with allergic rhinitis, including both seasonal (SAR) and perennial (PAR) allergies. The evidence primarily comes from short-term placebo-controlled RCTs and systematic reviews. Research explored outcomes related to physical discomfort and functional imbalance by monitoring changes in objective measurements like the Total Nasal Symptom Score (TNSS). Furthermore, the use of Montelukast in combination with other active ingredients, such as an antihistamine, was evaluated in specific trials. Studies comparing Montelukast against intranasal corticosteroids for specific outcomes, such as severe nasal congestion, reported differing measured patterns.

Studies in Specific Populations and Long-Term Follow-up

Montelukast was evaluated in studies involving a wide range of populations, including pediatric patients across different age groups, sometimes as young as 12 months. Long-term data from real-world observational studies and patient registries also exists, tracking outcomes reflecting daily functioning over extended time intervals. However, follow-up durations were limited in the primary effectiveness trials, and data for certain specific populations, such as older adults, remain insufficient. Evidence is limited against alternative preventive therapies for Exercise-Induced Bronchoconstriction (EIB), and long-term effects are not fully established for sustained effectiveness over many months or years.

Key Studies & References

1. Asthma diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) - NICE Guideline [NG245] (Relevant LTRA use in step-up therapy)
2. Montelukast: reminder of the risk of neuropsychiatric reactions - UK Government/MHRA Drug Safety Update

Common questions about Алмонт (FAQ)

Q: How quickly can I expect to notice any difference after starting Алмонт?

After taking a 10-mg tablet, the mean peak plasma concentration (C max) of the main active ingredient is typically reached in 3 to 4 hours. This measure of absorption indicates the time when the drug is circulating at its highest level.

Q: How long does the effect of one dose of Алмонт usually last?

The mean plasma half-life (t1/2) of the main active ingredient ranges from approximately 2.7 to 5.5 hours in healthy young adults. Since this medication is intended for chronic, long-term management, daily dosing aims to maintain a steady level in the body.

Q: Do many people report feeling tired after taking Алмонт?

Official safety information for the active ingredient lists fatigue (tiredness) as a reported adverse reaction. This symptom is generally listed among the less common side effects reported in regulatory documents.

Q: Does Алмонт interact with caffeine or alcohol?

Official documentation for the main active ingredient typically does not list a specific interaction with caffeine. However, other components in combination variants may have specific restrictions related to Central Nervous System (CNS) impairment, including caution regarding alcohol.

Q: What should I do if I forget to take a dose of Алмонт?

Official patient information advises that if a dose is missed, it should be taken as soon as it is remembered. The next dose should then be taken at the usual time, and official recommendations advise against taking two doses to make up for the missed one.

Q: Can I take Алмонт with my daily vitamins or supplements?

Official documents describe that complementary medicines, herbal remedies, and supplements are not typically tested for their interactions with this medicine. Regulatory guidance describes the importance of informing a healthcare provider about all products being taken.

Q: Is it known if Алмонт is safe to use during pregnancy?

The manufacturer makes no recommendation regarding use during pregnancy. Available data from studies have not established an associated increase in major birth defects, but there are no controlled human studies.

Q: If I stop taking Алмонт, will my original condition immediately return?

The regulatory guidance advises that if certain serious adverse events occur, the medication should be discontinued immediately. Symptoms have been reported to resolve in many cases following cessation of therapy.

Q: Is a prescription always required to get Алмонт?

Montelukast (the active ingredient) is officially classified as a prescription-only medication in major regulatory jurisdictions.

Q: How is Алмонт eliminated from the body?

The main active ingredient and its metabolites are eliminated almost exclusively via the bile and are recovered primarily in fecal collections. Minimal elimination occurs via urine.

Q: Does the regulatory label for Алмонт include warnings about operating heavy machinery?

The official label advises patients to be alert for adverse reactions such as dizziness, sleep disturbances, and other neuropsychiatric events that may affect the ability to perform tasks requiring focus, such as operating heavy machinery.

Q: What if I take Алмонт and don't feel any difference?

Regulatory guidance emphasizes that the medication should be used for allergic rhinitis only if there is an inadequate response to or intolerance to alternative therapies, underscoring the fact that the efficacy of treatment may be reviewed by a healthcare provider.

Q: Is Алмонт known to cause any skin reactions or rashes?

Regulatory safety summaries list rash as a reported adverse reaction. In rare cases, more serious events, such as those consistent with Systemic Eosinophilia, which may involve skin symptoms, have been reported.

Q: Do the side effects of Алмонт get better over time?

For certain common side effects, such as headaches, patient guidance indicates that the symptoms may improve or resolve after the first week of taking the medicine.

Q: Is it possible to become dependent on Алмонт?

The main active ingredient is not classified as a controlled substance and official information does not indicate that it has addictive properties or a potential for abuse.

Q: Does the packaging for Алмонт contain patient information leaflets?

Official regulatory bodies generally require that the medication packaging contain a Patient Information Leaflet (or Consumer Medicine Information) to provide important safety and usage details.

Q: Are there any reported interactions with common cold or flu medications?

While official documents may list compatibility with certain everyday painkillers, the broad range of common cold and flu medications means that the full list of ingredients is described as requiring review by a healthcare provider for potential interactions.

Q: Is it possible to take too much of Алмонт?

Official patient information advises that if more than the recommended dose is taken, official advice is that medical consultation be sought immediately.

How to Store and Dispose of Алмонт

The storage and disposal of Алмонт (Montelukast) must adhere strictly to regulatory requirements to ensure product stability and safety.

Storage Requirements

Алмонт must be stored at controlled room temperature, specifically maintained between 20 C and 25 C (68 F to 77 F). The medication requires protection from both light and moisture, necessitating storage in the original container with the cap kept tightly closed. It is a mandatory requirement that the product be stored out of the sight and reach of children at all times.

Disposal Instructions

Expired or unused Алмонт should be discarded by utilizing an official drug take-back program or an authorized collector, which is the preferred disposal method. If a take-back program is unavailable, the medicine may be disposed of in the household trash after being mixed with an undesirable substance and sealed in a container. Regulatory documents explicitly state that the medicine must not be disposed of by flushing down the toilet or sink.